TY - JOUR
T1 - Magnetic resonance elastography to study the effect of amyloid plaque accumulation in a mouse model
AU - Palotai, Miklos
AU - Schregel, Katharina
AU - Nazari, Navid
AU - Merchant, Julie P.
AU - Taylor, Walter M.
AU - Guttmann, Charles R.G.
AU - Sinkus, Ralph
AU - Young-Pearse, Tracy L.
AU - Patz, Samuel
N1 - Funding Information:
M.P. has received personal compensation for consulting for ITineris Kft. K.S., N.N., J.P.M., W.M.T., R.S., T.L.Y. and S.P. report no disclosures. C.R.G has received research funding from Sanofi, the National Multiple Sclerosis Society, and the International Progressive Multiple Sclerosis Alliance, the U.S. Office for Naval Research, as well as travel support from Roche Pharmaceuticals; C.R.G owns stock in Roche, Novartis, GSK, Alnylam, Protalix Biotherapeutics, Arrowhead Pharmaceuticals, Cocrystal Pharma, and Sangamo Therapeutics.
Funding Information:
This work was supported by the National Institutes of Health (grant number NIH R21 EB020757), the European Commission Horizon 2020 (proposal 668039) and from Boston University College of Engineering and the Brigham and Women's Hospital Department of Radiology. K.S. received funding from the German Research Foundation (DFG, SCHR 1542/1‐1).
Funding Information:
informationThis work was supported by the National Institutes of Health (grant number NIH R21 EB020757), the European Commission Horizon 2020 (proposal 668039) and from Boston University College of Engineering and the Brigham and Women's Hospital Department of Radiology. K.S. received funding from the German Research Foundation (DFG, SCHR 1542/1-1).M.P. has received personal compensation for consulting for ITineris Kft. K.S., N.N., J.P.M., W.M.T., R.S., T.L.Y. and S.P. report no disclosures. C.R.G has received research funding from Sanofi, the National Multiple Sclerosis Society, and the International Progressive Multiple Sclerosis Alliance, the U.S. Office for Naval Research, as well as travel support from Roche Pharmaceuticals; C.R.G owns stock in Roche, Novartis, GSK, Alnylam, Protalix Biotherapeutics, Arrowhead Pharmaceuticals, Cocrystal Pharma, and Sangamo Therapeutics.
Publisher Copyright:
© 2022 American Society of Neuroimaging.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Background and Purpose: Biomechanical changes in the brain have not been fully elucidated in Alzheimer's disease (AD). We aimed to investigate the effect of β-amyloid accumulation on mouse brain viscoelasticity. Methods: Magnetic resonance elastography was used to calculate magnitude of the viscoelastic modulus (|G*|), elasticity (Gd), and viscosity (Gl) in the whole brain parenchyma (WB) and bilateral hippocampi of 9 transgenic J20 (AD) mice (5 males/4 females) and 10 wild-type (WT) C57BL/6 mice (5 males/5 females) at 11 and 14 months of age. Results: Cross-sectional analyses showed no significant difference between AD and WT mice at either timepoints. No sex-specific differences were observed at 11 months of age, but AD females showed significantly higher hippocampal |G*| and Gl and WB |G*|, Gd, and Gl compared to both AD and WT males at 14 months of age. Similar trending differences were found between female AD and female WT animals but did not reach significance. Longitudinal analyses showed significant increases in hippocampal |G*|, Gd, and Gl, and significant decreases in WB |G*|, Gd, and Gl between 11 and 14 months in both AD and WT mice. Each subgroup showed significant increases in all hippocampal and significant decreases in all WB measures, with the exception of AD females, which showed no significant changes in WB |G*|, Gd, or Gl. Conclusion: Aging had region-specific effects on cerebral viscoelasticity, namely, WB softening and hippocampal stiffening. Amyloid plaque deposition may have sex-specific effects, which require further scrutiny.
AB - Background and Purpose: Biomechanical changes in the brain have not been fully elucidated in Alzheimer's disease (AD). We aimed to investigate the effect of β-amyloid accumulation on mouse brain viscoelasticity. Methods: Magnetic resonance elastography was used to calculate magnitude of the viscoelastic modulus (|G*|), elasticity (Gd), and viscosity (Gl) in the whole brain parenchyma (WB) and bilateral hippocampi of 9 transgenic J20 (AD) mice (5 males/4 females) and 10 wild-type (WT) C57BL/6 mice (5 males/5 females) at 11 and 14 months of age. Results: Cross-sectional analyses showed no significant difference between AD and WT mice at either timepoints. No sex-specific differences were observed at 11 months of age, but AD females showed significantly higher hippocampal |G*| and Gl and WB |G*|, Gd, and Gl compared to both AD and WT males at 14 months of age. Similar trending differences were found between female AD and female WT animals but did not reach significance. Longitudinal analyses showed significant increases in hippocampal |G*|, Gd, and Gl, and significant decreases in WB |G*|, Gd, and Gl between 11 and 14 months in both AD and WT mice. Each subgroup showed significant increases in all hippocampal and significant decreases in all WB measures, with the exception of AD females, which showed no significant changes in WB |G*|, Gd, or Gl. Conclusion: Aging had region-specific effects on cerebral viscoelasticity, namely, WB softening and hippocampal stiffening. Amyloid plaque deposition may have sex-specific effects, which require further scrutiny.
KW - Alzheimer's disease
KW - brain parenchyma
KW - hippocampus
KW - J20 mice
KW - magnetic resonance elastography
KW - MRE
KW - sex
UR - http://www.scopus.com/inward/record.url?scp=85127585525&partnerID=8YFLogxK
U2 - 10.1111/jon.12996
DO - 10.1111/jon.12996
M3 - Article
AN - SCOPUS:85127585525
SN - 1051-2284
VL - 32
SP - 617
EP - 628
JO - Journal of Neuroimaging
JF - Journal of Neuroimaging
IS - 4
ER -